Allogeneic Peripheral Blood Stem Cell Transplantation Significantly Increases the Risk of Chronic Graft-Versus-Host Disease of Lung Compared to Bone Marrow Transplantation  by Alam, N. et al.
S360 Poster Session II(43.26 13 nmol/mg proteins) declined by 33% (p5 0.05) relative
to Syn group (686 16 nmol/mg proteins), indicating impaired GSH
synthesis. Additionally, a significant twofold (p5 0.0007) rise in he-
patic homocysteine and ophthalmic acid levels were detected in Allo
mice, linking both SAA and redox metabolic imbalance to GVHD.
To investigate mechanism(s) of GSH redox loss in GVHD, he-
patic mRNA and protein levels of gamma-glutamylcysteine ligase
[GCLC (rate-limiting enzyme)], were quantified. The hepatic
GCLC transcript and protein declined in Allo compared to Syn
mice [GCLC fold change: day +4 5 0.4 vs 1.0360.15; day +10 5
0.36 0.05 vs 1.06 0.05 (p 5 0.0004), respectively]. Target organs
like lungs and gut also revealed depletion of intracellular thiol in
Allo mice that directly correlated with the degree of T cell infiltra-
tion. Together, these data show that the GSH synthetic pathway is
specifically affected in GVHD. The tight transcriptional deregula-
tion of GCLC with depletion of GSH reserve is an early event and
precedes histopathological changes of GVHD. Identification of
modifiers of GCLC/GSH/GSSG system may provide a novel target
for treatment of GVHD.422
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Background: Graft-versus-host disease (GVHD) is one of the
primary contributing factors to morbidity and mortality following
allogeneic stem cell transplantation. Methotrexate (MTX) has
been an integral component of prophylaxis regimens against
acute GVHD when combined with calcineurin inhibitors. Recent
data suggests that lower doses of MTX are effective in prevent-
ing aGVHD and may be associated with less toxicity. However,
few comparative studies have been performed between so called
mini-MTX and standard MTX dosing schemas. The primary ob-
jective of this analysis was to compare the incidence of acute
GVHD with standard versus mini-dose MTX prophylaxis. Sec-
ondary objectives evaluated the safety and the toxicity associated
with MTX administration.
Methods: This retrospective review included allogeneic stem cell
transplant recipients at Memorial Sloan-Kettering Cancer Center
(MSKCC) between 8/1/2003-8/16/2010 that received standard or
mini-MTX as part of post-transplant GVHD prophylaxis. Standard
MTX dosing was defined as 15 mg/m2 on day 1 with subsequent
doses of 10 mg/m2 administered on days 3, 6 and 11. The mini-
MTX group included patients who never received a dose of 15
mg/m2.
Results: 226 patients (138 standard and 88 mini-MTX) were in-
cluded in the analysis. Based on clinical practice at MSKCC,
the standard dose arm had a higher frequency of leukemia patients
while the mini-dose group had a higher frequency of lymphoma
patients. Median age at transplant was 27 years and 50 years for
standard and mini-dose groups, respectively (p\0.001). The me-
dian follow up for patients alive without acute GVHD was 33
months (range 10-90 months). Cumulative incidence of GVHD
at 3 months was 28.9% [95% CI: (21.4-36.6%)] and 28.4%
[95% CI (19.0-37.9%)] for the standard and mini-dose treatment
arms (p 5 0.91). The adult subgroup also revealed no difference
in aGVHD at 3 months (p 5 0.56). A univariate analysis showed
that CMV seropositivity was positively associated with higher
rates of GVHD (HR: 1.81 [95% CI: 1.14-2.85, p 5 0.01). Dose
adjustments or delay of MTX were significantly different between
groups (43.5% in standard arm vs. 15.9% mini-dose arm,
p\0.0001) suggesting an improved toxicity profile, however this
may have been impacted by the primary conditioning regimen.
Conclusion: Prophylaxis with mini-MTX may be associated with
a similar incidence of aGVHD and an improved toxicity profile
when compared to a standard dose schema.423
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Strategies to suppress GVHD are often associated with broader
suppression of the immune system leading to a compromised
GVT effect. We have demonstrated that genetically engineered T
cells over-expressing TNF-Related Apoptosis Inducing Ligand
(TRAIL) have enhanced GVT effects and explicitly suppress
GVHD. TRAIL induces apoptotic signals through death receptor
(DR) 4 and 5 molecules (only DR5 in mice) expressed on certain tu-
mors and inducible on others. TRAIL is therefore an attractive can-
didate for genetic engineering of donor T cells to enhance their
GVT potential.
Mature T cells derived from donor B6 splenocytes were trans-
duced with a lentiviral TRAIL expression vector. The transduced
TRAIL+ T cells were adoptively transferred into lethally irradiated
CBF1 recipients of T cell depleted allografts and LB27.4 tumor to
assess their GVHD and GVT activity. TRAIL+ T cells displayed
significantly enhanced antitumor immunity compared to mock
(GFP)-transduced controls in vitro and upon transfer into tumor
bearing allo-BMT recipients (p\0.01, 100% survival in TRAIL+
T cell group). Additionally, the recipients treated with TRAIL+ T
cells had significantly less GVHD lethality and morbidity. This
was observed across multiple GVHD models (B6 / CBF1 and
B10.BR/ B6). Using in vitro proliferation assays and in vivo biolu-
minescent imaging, we found that TRAIL+ T cells suppressed pro-
liferation of non-transduced alloreactive T cells. To explore the
factors contributing to TRAIL-mediated suppression of GVHD,
we used recipients deficient in DR5 (DR5ko) and found that
TRAIL+ T cells suppress GVHD by impairing host APC functions.
Precursor (pre)T cells can regenerate the T cell compartment with-
out GVHD. We generated and expanded TRAIL+ preT cells using
the OP9-DL1 co-culture system. Adoptive transfer of B6 TRAIL+
preT cells into syngeneic-transplanted BALB/c mice reconstituted
the T cell compartment with TRAIL+ T cells and caused enhanced
antitumor activity (p\0.05) compared to controls.
Collectively, our data demonstrate that donor T cells genetically
engineered to expressTRAIL can enhanceGVTeffects and suppress
lethal GVHD through impairment of host APCs in recipients of
allo-HSCT. Furthermore, we demonstrated that allogeneic ex vivo
generated preT cells expressing TRAIL could mediate a strong pro-
tection against tumor challenge in syngeneic HSCT recipients, rep-
resenting an ‘‘off the shelf’’ strategy in both allogeneic and
autologous recipients.424
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION SIG-
NIFICANTLY INCREASES THE RISK OF CHRONIC GRAFT-VERSUS-HOST
DISEASE OF LUNG COMPARED TO BONE MARROW TRANSPLANTATION
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Introduction: Chronic graft versus host disease (GVHD) of lung is
associated with higher transplant related morbidity and mortality af-
ter allogeneic hematopoeitic cell transplant (HCT). Risk factors for
lung GVHD are not yet fully elucidated in detail. We attempted to
identify clinical risk factors for lung GVHD after allogeneic HCT
based on single center experience.
Methods: 401 patients were transplanted between year 2000 and
2007 at the Princess Margaret Hospital, Toronto, Canada. 280
(70%) and 121 (30%) patients received peripheral blood stem cell
(PBSC) and bonemarrow (BM) as a source of stem cells, respectively.
Monitoring with pulmonary function tests (PFT) were performed
prior to transplant, at day 180, then annually. PFT was also
Poster Session II S361performed when indicated clinically. CT scan of lung was performed
to confirm the diagnosis of lung GVHD and to exclude other infec-
tious causes. Bronchoscopic lavage was performed to exclude poten-
tial infectious cause if needed. Potential clinical risk factors for lung
GVHD were examined including conditioning, age, gender, source
of stem cell, diagnosis, disease status and previous episode of acute
GVHD.
Results:With median follow up of 1,122 days, 68 patients (16.9%)
had a diagnosis of chronic GVHD of lung with median onset of 349
days (range 71-1,880 days; 95% CI [299-398 days]), 53(78%) of
whom patients received myeloablative conditioning. Fifty
one(75%) patients received matched sibling donor transplant versus
17(25%) patients received unrelated donor. Overall survival rates re-
mained similar in both cohorts.
In the univariate analyses, other clinical risk factors were not asso-
ciated with the risk of chronic GVHD of lung: conditioning (p 5
0.9), age with cut off of 60 years (p5 0.4), donor type (p5 0.5), grade
II-IV acute GVHD (p 5 0.7), grade III-IV acute GVHD(p 5 0.4),
development of CMV reactivation (p 5 0.6). However, incidence
of chronic GVHD lung was significantly higher in the group receiv-
ing PBSC (13.86 2.4% at 1 year; 23.063.2% at 2 years) than in those
receiving BM (6.862.5% at 1 year; 1663.8% at 2 years; p 5 0.02,
hazard ratio 1.937, 95%CI [1.100-3.410]). Multivariate analyses
also confirmed PBSC transplantation as an independent risk factor
for chronic GVHD of lung (p 5 0.005, hazard ratio 2.359, 95%CI
[1.290-4.314]).
Conclusion: The use of PBSC increases the risk of lung GVHD
compared to the use of BM for allogeneic HCT. Closer monitoring
is warranted to detect lung GVHD early after PBSCT.425
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Introduction: Rapamycin (RAPA) inhibits the serine/threonine ki-
nase mammalian Target of Rapamycin, a crucial immune regulator.
Dendritic cells (DC) exposed to RAPA (RAPA-DC) enrich for
CD4+FoxP3+ regulatory T cells and induce alloreactive T cell apo-
ptosis. RAPA-DC promote experimental allograft survival, yet para-
doxically secrete increased IL-12, which is central for the generation
of IFN-g+CD4+ T helper type 1 cells. IFN-g can be pro-apoptotic
and IL-12-driven IFN-g inhibits graft-versus-host disease
(GVHD) following hematopoietic stem cell transplantation.We hy-
pothesized that IL-12hi RAPA-DC, unlike control (CTR)-DC
would be effective in the prevention of GVHD by supporting
IFN-g-mediated apoptosis of alloreactive T cells.
Methods: DC were generated from C57BL/6 (H2-b) or BALB/c
(H2-d) bone marrow (BM) in 7 day (d) culture in the presence or ab-
sence of RAPA. DC remained unstimulated or were LPS-stimulated
(100 ng/ml) for an additional 18 hours. CD11c+ DC were used as
stimulators of allogeneic CD4+ T cells in 5 d mixed leukocyte reac-
tion (MLR) with or without anti-IFN-g antibody. T cell apoptosis
was quantified using an Annexin V-PE Apoptosis Detection kit. In-
tracellular FoxP3 expression was determined by flow cytometry. The
capacity of DC to prevent GVHDwas assessed in irradiated BALB/c
mice reconstituted with 5x106 T cell-depleted B6 BM on d0. Recip-
ient mice received 1x106 CD11c+ BALB/c DC (CTR-, RAPA-, or
LPS-exposed DC) on d0 and 1x106 B6 T cells on d1. Mice were
monitored daily, and moribund mice or those with .20% weight
loss were euthanized.
Results: Compared to CTR-DC, especially when LPS-stimulated,
RAPA-DC induced increased apoptosis (Annexin V+7-AAD+) of al-
loreactive CD4+ T cells in MLR (Table 1). Neutralization of IFN-g
in co-cultures containing LPS-stimulated RAPA-DC decreased
levels of apoptosis to those of LPS-exposed CTR-DC. Depletion of
IFN-g did not impact on the Treg-enriching capacity of RAPA-DC.Further, whereas CTR-DC and LPS-exposed CTR-DC did not
prolong survival, LPS-treated RAPA-DC prolonged survival com-
parable to syngeneic controls. RAPA-DC prolonged survival nearing
statistical significance.
LPS-exposed RAPA-DC induce apoptosis of alloreactive CD4+
T cells via an IFN-g dependentmechanism and abrogate acute
GVHD
% CD4+ Annexin V+ Median
Group 7-AAD+ Survival (d)1 Syngeneic - >50d2 CTR-DC 7.1 ± 0.2 8e3 RAPA-DC 13.9 ± 1.6a 25f4 RAPA-DC + aIFNg 21.8 ± 13.7 -
5 CTR-DC + LPS 14.6 ± 3.6 11g6 RAPA-DC + LPS 30.6 ± 3.4b,c >50h7 RAPA-DC + LPS + aIFNg 18.4 ± 1.3 -
8 GVHD - 15ap 5 0.03 compared to group 2.
bp 5 0.04 compared to group 5.
cp 5 0.04 compared to group 7.
dp 5 0.03 compared to group 8.
ep 5 0.92 compared to group 8.
fp 5 0.07 compared to group 8.
gp 5 0.67 compared to group 8.
hp 5 0.005 compared to group 8 by 2-tailed Student’s t-test.
Conclusions: Increased apoptosis of CD4+ allogeneic T cells in-
duced by LPS-stimulated IL-12hi RAPA-DC is mediated through
IFN-g. Thus, increased IL-12 may support IFN-g-mediated activa-
tion-induced cell death while sparing regulatory T cells and underlie
the capacity of LPS-exposed RAPA-DC to prevent GVHD.426
HOST-DERIVED IL-22 PROTECTS INTESTINAL STEM CELLS FROM GVHD
Hanash, A.1, Dudakov, J.1, Hua, G.1, O’Connor, M.1, Jenq, R.1,
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IL-22 is a recently characterized cytokine that is produced by
helper T cells and innate lymphoid cells (ILC). Expression of its re-
ceptor (IL-22R) is limited to non-hematopoietic stromal cells, and it
mediates protection of intestinal epithelium during experimental co-
litis by providing a signal for epithelial cell survival, proliferation,
and wound healing. We investigated the role of IL-22 in GVHD
during MHC-mismatched C57BL/6 (B6) into BALB/c murine
bone marrow transplantation (BMT). Elimination of IL-22 with
neutralizing antibody led to increased GVHD mortality post-
BMT in comparison to isotype control. IL-22 KO BMT recipients
demonstrated significantly increased GVHD mortality. The critical
role of recipient-derived IL-22 was confirmed in a minor antigen-
mismatched LP into B6 BMTmodel, and IL-22 KO recipients again
demonstrated significantly increased mortality during GVHD and
histopathologic evidence of GVHD in the small and large intestine
and liver. IL-22 ELISA on tissue homogenates following BMT
with wild type donors and recipients indicated that IL-22 levels
were increased post-BMT in small and large intestine. However,
IL-22 was significantly reduced in both tissues during GVHD. We
identified IL-22-producing host ILC in small intestine lamina prop-
ria two weeks post-BMT. ILC were the only IL-22-producing pop-
ulation that could be identified post-BMT, and these ILC were
significantly reduced during GVHD. IL-22R expression was identi-
fied by immunohistochemistry in intestinal crypts where the stem/
progenitor cell niche is located, and immunofluorescence demon-
strated IL-22R expression on intestinal progenitors at the crypt
apex and on intestinal stem cells (ISC) located between lysozyme-ex-
pressing Paneth cells. Use of Lgr5-LacZ reportermice indicated that
ISC were targets of GVHD, and histologic assessment of the ISC
